Perion to Announce Its First Quarter 2026 Financial Results on May 20, 2026

Perion to Announce Its First Quarter 2026 Financial Results on May 20, 2026

NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–Perion Network Ltd. (NASDAQ & TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced it plans to release its financial results for the first quarter 2026 prior to the opening of the financial markets on Wednesday, May 20, 2026.

Tal Jacobson, CEO, and Elad Tzubery, CFO, will host a conference call to discuss the results on that day at 8:30 a.m. ET.

Earning call registration link: https://perion-q1-2026-earnings-call.open-exchange.net/

A replay of the call and a transcript will be available within approximately 24 hours of the live event on Perion’s website at www.perion.com/investors.

About Perion

Perion is helping agencies, brands and retailers get better results with their marketing investments by providing advanced technology across digital channels. Through the Perion One platform, we are making digital advertising more effective by building solutions that continuously adapt to connect the dots between data, creative and channels.

For more information, visit Perion’s website at www.perion.com.

Forward Looking Statements

This press release contains historical information and forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the safe- harbor provisions of the Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of Perion. The words “will,” “believe,” “expect,” “intend,” “plan,” “should,” “estimate” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of Perion with respect to future events and are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. Many factors could cause the actual results, performance or achievements of Perion to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, but not limited to, political, economic and other developments (including the current war between Israel and Hamas and other armed groups in the region), the failure to realize the anticipated benefits of companies and businesses we acquired and may acquire in the future, risks entailed in integrating the companies and businesses we acquire, including employee retention and customer acceptance, the risk that such transactions will divert management and other resources from the ongoing operations of the business or otherwise disrupt the conduct of those businesses, and general risks associated with the business of Perion including, loss of, or reduction in our business with, key customers or other partners that are material to our business, the impact of the rapid development and broad adoption of generative AI on our business, the transformation in our strategy, intended to unify our business units under the Perion brand (Perion One), intense and frequent changes in the markets in which the businesses operate and in general economic and business conditions (including the fluctuation of our share price), armed conflicts with Iran and other parties, the outcome of any pending or future proceedings against Perion, data breaches, cyber-attacks and other similar incidents, unpredictable sales cycles, competitive pressures, market acceptance of new products and of the Perion One strategy, changes in applicable laws and regulations as well as industry self-regulation, negative or unexpected tax consequences, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, whether referenced or not referenced in this press release. We urge you to consider those factors, together with the other risks and uncertainties described in our most recent Annual Report on Form 20-F for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (SEC) on March 16, 2026, and our other reports filed with the SEC, in evaluating our forward-looking statements and other risks and uncertainties that may affect Perion and its results of operations. Perion does not assume any obligation to update these forward-looking statements.

Perion Network Ltd.

Dudi Musler, VP of Investor Relations

+972 (54) 7876785

[email protected]

KEYWORDS: New York United States North America Israel Middle East

INDUSTRY KEYWORDS: Technology Content Marketing Marketing Advertising Communications Software Digital Marketing Data Management Artificial Intelligence

MEDIA:

Logo
Logo

Gilat Awarded over $7 Million for its New EnduroStream Solution to Support the U.S. Department of War

Gilat Defense establishing a new defense market category for high‑power resilient SSPAs

PETAH TIKVA, Israel, April 29, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that Gilat Defense received an order for over $7 million through a prime contractor to support the U.S. Department of War for its Gilat Wavestream’s EnduroStream solid‑state power amplifier (SSPA) solution. Delivery is expected over the next 24 months.

This significant order for the EnduroStream product line opens a new market category within the defense sector. EnduroStream has introduced a new class of high‑power SSPAs with built‑in resiliency, designed to replace traveling wave tube amplifiers (TWTAs) in gateways and high‑power terminal applications. EnduroStream delivers the power levels required for mission‑critical defense environments while offering improved reliability, operational resilience, and lifecycle advantages over traditional TWTA‑based solutions.

“This order confirms the need for a purpose‑built, high‑power solid‑state solution that delivers the inherent advantages of SSPAs while meeting stringent power and resiliency requirements for modern military SATCOM,” said Edgar Khachatryan, President, Gilat Wavestream. “It clearly establishes EnduroStream as a solution for defense customers looking to modernize ground infrastructure and transition to more resilient and maintainable architectures without compromising performance.”

About Gilat

Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With over 35 years of experience, we develop and deliver deep technology solutions for satellite, ground, and new space connectivity, offering next-generation solutions and services for critical connectivity across commercial and defense applications. We believe in the right of all people to be connected and are united in our resolution to provide communication solutions to all reaches of the world.

Together with our wholly owned subsidiaries Gilat Wavestream, Gilat DataPath, and Gilat Stellar Blu, we offer integrated, high-value solutions supporting multi-orbit constellations, Very High Throughput Satellites (VHTS), and Software-Defined Satellites (SDS) via our Commercial and Defense Divisions. Our comprehensive portfolio is comprised of a software-defined platform and modems, high-performance satellite terminals, advanced Satellite On-the-Move (SOTM) antennas and Electronically Steered Antennas (ESAs), highly efficient, high-power Solid State Power Amplifiers (SSPA) and Block Upconverters (BUC) and includes integrated ground systems for commercial and defense markets, field services, network management software, and cybersecurity services.

Gilat’s products and tailored solutions support multiple applications including government and defense, IFC and mobility, cellular backhaul, enterprise, aerospace and critical infrastructure clients all while meeting the most stringent service level requirements. For more information, please visit: http://www.gilat.com

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Gilat to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, inability to maintain market acceptance to Gilat’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for Gilat’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology and risks associated with Gilat’s international operations and its location in Israel, including those related to the hostilities between Israel and Iran and the Hezbollah in Lebanon. For additional information regarding these and other risks and uncertainties associated with Gilat’s business, reference is made to Gilat’s reports filed from time to time with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.

Contact:

Gilat Satellite Networks

[email protected]



CorVel Corporation Launches CorVel Connected™, an AI-Powered Claims Intelligence Layer Embedded in CareMC®

Supporting faster, more consistent end-to-end claim management by embedding decision-support intelligence directly into daily workflows—without replacing human judgment

FORT WORTH, Texas, April 29, 2026 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, today announced the launch of CorVel Connected™, the company’s unified technology brand for artificial intelligence-powered innovation within its CareMC® claims management platform. CorVel Connected embeds intelligence directly into claim workflows, surfacing the most relevant information and actionable insights in real time so claims professionals can make faster, more informed decisions. The platform ensures critical context is delivered at the point of need while preserving accountability and decision-making authority with the claims professional.

CorVel Connected is built to address a fundamental shift in claims management: professionals are now expected to sift through an ever-expanding volume of data tied to each claim—medical records, notes, communications, and external inputs—making it increasingly difficult to identify what actually matters. The challenge is no longer access to information, but the burden of navigating it. By organizing, prioritizing, and summarizing relevant data in real time, CorVel Connected reduces that noise, enabling claims professionals to focus on informed judgment, faster decisions, and more consistent outcomes across both individual claims and entire programs.

One of the first capabilities launched under CorVel Connected, AI-powered Claims Summarization and Decision Support, directly addresses the growing burden of navigating complex claim files. It significantly reduces the time required to review claim histories and supporting documentation by rapidly synthesizing large volumes of activity into clear, consistent summaries. These summaries are presented for human review and interpretation, allowing claims professionals, supervisors, and management to spend less time searching for information and more time driving investigation, action plans, reserving, and resolution.

“As claim volumes rise and documentation becomes more complex, efficiency at the claim desk is critical,” said Ryan Murphy, Vice President, Product, Enterprise Claims at CorVel. “CorVel Connected ensures the right information is surfaced quickly, but outcomes still depend on human judgment. Technology should strengthen decisions, not replace them.”

A Connected Suite of Embedded Intelligence

CorVel Connected is more than a single feature; it is a branded suite of AI-enabled capabilities embedded directly within CareMC®, designed to enhance consistency, accessibility, and decision support where work happens. Capabilities within CorVel Connected include:

  • AI-powered claim summarization that synthesizes claim histories into clear, review-ready narratives
  • Natural-language question-and-answer functionality that allows users to ask direct questions about claims or programs without navigating complex reports
  • CorVel’s Generative AI Document Viewer™ that delivers real‑time medical document summaries for faster claim review
  • Intelligent claim assignment aligned to complexity, jurisdiction, and expertise
  • Activity Note Automation generated as work is performed, with required adjuster review and signoff
  • Integrated email capture and prioritization to reduce manual sorting and missed activity
  • Recommended next actions and structured plans of action, with milestone tracking to support consistent execution
  • Reserve predictions with clear explanations, designed to inform—not override—adjuster judgment

Together, these capabilities return time to the claim desk, improve consistency across reviews, and ensure intelligence is delivered directly inside existing workflows, without forcing users into separate tools or disconnected systems.

Extending Insight Beyond the Claim Desk

CorVel Connected is also envisioned as a shared-value platform for both internal teams and clients. Through enhanced, client-facing executive dashboards, organizations can ask higher-level questions about program performance, trends, and concentration patterns, transforming complex claims data into actionable insights that support smarter business decisions and prevention strategies.

“At CorVel, we are redefining claims management by pairing deep human expertise with intelligent, technology-driven augmentation,” said Michael Combs, President and CEO of CorVel. “CorVel Connected demonstrates our commitment to outcome-led innovation, using AI to accelerate speed and consistency, without losing the human insight essential to better care and outcomes.”

To learn more about CorVel Connected and CorVel’s CareMC® claims management platform, visit: https://www.corvel.com/technology/caremc/

About CorVel

CorVel Corp. applies technology, including artificial intelligence, machine learning, and natural language processing, to enhance the management of episodes of care and related health care costs. We partner with employers, third-party administrators, insurance companies, and government agencies in managing workers’ compensation and health, auto, and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support our partners and their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change Such forward-looking statements include, but are not limited to, statements relating to the Company’s services and the Company’s continued investment in these and other innovative technologies, and statements relating to the Company’s product offerings. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement results of operations and financial condition is greater than our initial assessment. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June, 30, 2025, September 30, 2025 and December 31, 2025. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com



Kornit Digital Sets First Quarter 2026 Earnings Release Date and Webcast

ROSH-HA’AYIN, Israel, April 29, 2026 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production, announced today that it will release its financial results for the first quarter ended March 31, 2026, on Wednesday, May 13, prior to the market open.

The Company will host an earnings conference call and webcast reviewing these results and its operations on Wednesday, May 13, 2026, at 8:30 am ET. This conference call will be broadcast live and can be accessed by all interested parties through Kornit’s website, www.kornit.com, in the “Investors” section.

The dial-in information for the live call is:

  • Live Call: 1-877-407-0792 or 1-201-689-8263
  • Israel Toll Free: 1 809 406 247

A replay of the call will be archived on the Company’s website. Alternatively, the replay can be accessed via dial-in, available approximately three hours after the completion of the live call until 11:59 pm ET on May 27, 2026.

  • Replay: 1-844-512-2921 or 1-412-317-6671
  • Replay ID: 13759148

About Kornit Digital

Kornit Digital (NASDAQ: KRNT) is a worldwide market leader in sustainable, on-demand, digital fashion and textile production technologies. The Company offers end-to-end solutions including digital printing systems, inks, consumables, software, and fulfillment services through its global fulfillment network. Headquartered in Israel with offices in the USA, Europe, and Asia Pacific, Kornit Digital serves customers in more than 100 countries. To learn more, visit www.kornit.com.

Investor Contact

Andrew G. Backman
Chief Capital Markets Officer
[email protected]



Anika Reports First Quarter 2026 Financial Results

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing

Delivered 64% gross margin, +8 points year over year, driven by improved operational execution

Operational transformation generating early wins, delivering $4 million of adjusted EBITDA

BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026.

Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-year period, representing growth of 13%. Growth was driven by strength across both channels, with OEM Channel revenue of $17.0 million, up 14%, and Commercial Channel revenue of $12.6 million, up 12% year-over-year.

Gross profit for the first quarter was $19.0 million, compared to $14.7 million in the prior-year period. Gross margin improved to 64.2%, compared to 56.1% in the first quarter of 2025, driven by operational execution, ongoing margin improvement initiatives and favorable product mix.

Total operating expenses were $24.5 million, compared to $19.0 million in the prior-year period, primarily reflecting $4.9 million of one-time severance costs. Remaining increases were largely related to investments in operations and research and development expenses to support ongoing programs.

Adjusted EBITDA for the first quarter of 2026 was $4.3 million, compared to $0.1 million in the first quarter of 2025, reflecting strong gross margin expansion and disciplined operational execution.

“Our strategic transformation and organizational realignment is yielding results and driving improved profitability and efficiencies throughout the organization,” said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. “We delivered a strong start to 2026, highlighted by double-digit revenue growth and gross margin expansion, which improved adjusted EBITDA. These results were led by strong growth in our Commercial Channel with Regenerative Solutions increasing 20% year over year, driven by 35% US procedure growth from Integrity, which generated $1.8 million in revenue during the quarter. In addition, OEM Channel performance reflected a combination of favorable order timing, lower 2025 sales volume, and solid execution by our teams to start 2026, contributing to a 14% revenue increase year over year.

Our margin performance in the first quarter demonstrates the leverage in our business model as volume scales and operational initiatives take hold, including the deployment of lean manufacturing principles that are enabling our teams to increase throughput and drive improved performance. These initiatives are designed to support our operations as we advance our portfolio through FDA review and position the company to scale production in anticipation of future growth. At the same time, we continue to make targeted investments across our regenerative pipeline and commercial business to position Anika for sustainable, profitable long-term growth.”

First Quarter 2026 Business Highlights and Current Business Updates

  • International OA Pain Management grew 9% in the first quarter reaching $8.9 million, led by continued regional expansion and improved market share.
  • Integrity continued to demonstrate strong momentum, with U.S. sales execution driving a 35% increase in procedures year over year and generating $1.8 million in revenue. Growth was driven by sustained surgeon adoption in the U.S., the successful launch of larger Integrity sizes that expand addressable tendon applications, and increasing international penetration.
  • Hyalofast PMA engagement with FDA continues to progress and review timeline remains in line with the previously provided timeline.
  • Cingal bioequivalence study enrollment remains on track in preparation for an FDA NDA submission including necessary CMC work to support HA as a drug.
  • OEM channel year over year growth driven by order timing of non-orthopedic and US OA Pain Management products including continued strong Monovisc demand
  • Targeted operational investments improving productivity, discipline, and scalability

First Quarter 2026 Continuing Operations Financial Summary

  • Revenue $29.6 million, up 13% year over year
  • Commercial Channel revenue $12.6 million, up 12%
  • OEM Channel revenue $17.0 million, up 14%
  • Gross margin 64.2%
  • Operating expenses $24.5 million, including $4.9 million of one-time severance expenses
  • GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share
  • Adjusted net income from continuing operations1 $3.8 million, $0.27 per diluted share
  • Adjusted EBITDA1 $4.3 million
  • Cash and cash equivalents $41.0 million as of March 31, 2026

1 See description of non-GAAP financial information contained in this release.

Fiscal 2026 Guidance

Anika is maintaining the previously provided 2026 guidance:

  • Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year
    • Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year
    • OEM Channel, $61 to $64.5 million, flat to modestly lower year over year
  • Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.

Company Completes $15 Million 10b5-1 Share Repurchase

The company completed its previously announced $15 million 10b5-1 share repurchase on April 10, 2026, with an average price of $10.76 per share.

Corporate Governance Update

As disclosed in the Company’s definitive proxy statement filed on April 28, 2026, Dr. Glenn Larsen and Bill Jellison have informed the Board of their intention to step down as directors as of the 2026 Annual Meeting as part of the Company’s continued transformation, with neither resignation related to any disagreement with the Company, management, or the Board.

The Company is grateful to Dr. Larsen and Mr. Jellison for their dedication and valuable contributions to Anika.

Conference Call and Webcast Information

Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Wednesday, April 29, 2026, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

Non-GAAP Financial Information

1


Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

Adjusted EBITDA

Adjusted EBITDA is defined by the Company as GAAP net income (loss) from continuing operations excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, and shareholder activism costs.

Adjusted Net Income (Loss) from Continuing Operations and Adjusted EPS from Continuing Operations

Adjusted net income (loss) is defined by the Company as GAAP net income from continuing operations, on a tax effected basis, excluding stock-based compensation. Adjusted diluted EPS from continuing operations is defined by the Company as GAAP diluted EPS from continuing operations excluding stock-based compensation.

A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

Forward-Looking Statements

This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company’s expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact,
including statements in the section titled “Fiscal 2026
Guidance” regarding 2026 revenue and adjusted EBITDA
. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support, or to timely file domestic and international pre-market approval applications, 510(k) applications, or new drug applications, including the PMA for Hyalofast and the NDA for Cingal; (iii) that the FDA or other regulatory bodies may not approve or clear the Company’s applications, including the Hyalofast PMA because of the failure to achieve the pre-defined primary endpoints or because the FDA may determine that achievement of secondary endpoints and/or post hoc data analyses are not sufficient to support approval; (iv) that such approvals or clearances will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (v) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (vi) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vii) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (viii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (ix) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (x) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (xi) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website at 


www.sec.gov


. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

For Investor Inquiries:

Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
[email protected]

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
                   
    For the Three Months Ended March 31,   For the Three Months Ended March 31,
      2026       2025       2026       2025    
Revenue   $ 29,612     $ 26,168     $ 29,612     $ 26,168    
Cost of Revenue     10,615       11,487       10,615       11,487    
Gross Profit     18,997       14,681       18,997       14,681    
                   
Operating expenses:                  
Research and development     6,713       6,059       6,713       6,059    
Selling, general and administrative     17,772       12,906       17,772       12,906    
Total operating expenses     24,485       18,965       24,485       18,965    
Loss from operations     (5,488 )     (4,284 )     (5,488 )     (4,284 )  
Interest and other income (expense), net     667       415       667       415    
Loss before income taxes     (4,821 )     (3,869 )     (4,821 )     (3,869 )  
Provision for income taxes     235       89       235       89    
Loss from continuing operations     (5,056 )     (3,958 )     (5,056 )     (3,958 )  
Loss from discontinued operations, net of tax           (915 )           (915 )  
Net loss   $ (5,056 )   $ (4,873 )   $ (5,056 )   $ (4,873 )  
                   
Net loss per share:                  
Basic                  
Continuing Operations   $ (0.37 )   $ (0.28 )   $ (0.37 )   $ (0.28 )  
Discontinued Operations   $     $ (0.06 )   $     $ (0.06 )  
    $ (0.37 )   $ (0.34 )   $ (0.37 )   $ (0.34 )  
                   
Diluted                  
Continuing Operations   $ (0.37 )   $ (0.28 )   $ (0.37 )   $ (0.28 )  
Discontinued Operations   $     $ (0.06 )   $     $ (0.06 )  
    $ (0.37 )   $ (0.34 )   $ (0.37 )   $ (0.34 )  
                   
Weighted average common shares outstanding:                  
Basic     13,531       14,297       13,531       14,297    
Diluted     13,531       14,297       13,531       14,297    
                   

Anika Therapeutics, Inc. and Subsidiaries  
Consolidated Balance Sheets  
(in thousands, except per share data)  
(unaudited)  
         
  March 31,   December 31,  
ASSETS   2026       2025    
Current assets:        
Cash and cash equivalents $ 41,020     $ 57,481    
Accounts receivable, net   25,768       23,690    
Inventories, net   22,838       18,787    
Prepaid expenses and other current assets   3,935       3,400    
Total current assets   93,561       103,358    
Property and equipment, net   39,722       40,324    
Right-of-use assets   25,430       25,939    
Other long-term assets   4,303       4,034    
Notes receivable   5,679       5,636    
Deferred tax assets   1,150       1,275    
Intangible assets, net   1,650       1,650    
Goodwill   7,892       8,054    
Total assets $ 179,387     $ 190,270    
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities:        
Accounts payable $ 6,339     $ 6,041    
Accrued expenses and other current liabilities   14,627       15,867    
Total current liabilities   20,966       21,908    
Other long-term liabilities   726       701    
Lease liabilities   23,794       24,196    
         
Stockholders’ equity:        
Common stock, $0.01 par value   133       139    
Additional paid-in-capital   83,347       87,498    
Accumulated other comprehensive loss   (5,310 )     (4,959 )  
Retained earnings   55,731       60,787    
Total stockholders’ equity   133,901       143,465    
Total liabilities and stockholders’ equity $ 179,387     $ 190,270    
         
Anika Therapeutics, Inc. and Subsidiaries  
Consolidated Statements of Cash Flows  
(in thousands)  
(unaudited)  
  For the Three Months Ended March 31,  
    2026       2025    
Cash flows from operating activities:        
Net loss $ (5,056 )   $ (4,873 )  
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation   1,407       1,383    
Amortization of acquisition related intangible assets         209    
Non-cash operating lease cost   464       577    
Stock-based compensation expense   6,641       2,863    
Deferred income taxes   108       18    
Provision for doubtful accounts   (24 )     (346 )  
Provision for inventory   1,032       832    
Interest income on notes receivable   (179 )     (224 )  
Gain on sale of assets   (52 )     (300 )  
Changes in operating assets and liabilities:        
Accounts receivable   (2,180 )     3,034    
Inventories   (5,407 )     523    
Prepaid expenses, other current and long-term assets   (1,728 )     (203 )  
Accounts payable   745       47    
Operating lease liabilities   (468 )     (569 )  
Accrued expenses, other current and long-term liabilities   (1,339 )     (3,088 )  
Income taxes   1,190       (13 )  
Net cash provided by operating activities   (4,846 )     (130 )  
         
Cash flows from investing activities:        
Purchases of property and equipment   (1,431 )     (2,824 )  
Proceeds from sale of Parcus         4,496    
Note receivable   192          
Net cash used in investing activities   (1,239 )     1,672    
         
Cash flows from financing activities:        
Repurchases of common stock   (8,690 )     (3,971 )  
Cash paid for tax withheld on vested restricted stock awards   (1,657 )     (1,467 )  
Net cash used in financing activities   (10,347 )     (5,438 )  
         
Exchange rate impact on cash   (29 )     108    
         
Increase (decrease) in cash and cash equivalents   (16,461 )     (3,788 )  
Cash and cash equivalents at beginning of period   57,481       57,159    
Cash and cash equivalents at end of period $ 41,020     $ 53,371    
         
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA
(in thousands)
(unaudited)
             
  For the Three Months Ended March 31, For the Years Ended March 31,
    2026       2025     2026       2025  
Loss from continuing operations $ (5,056 )   $ (3,958 ) $ (5,056 )   $ (3,958 )
Interest and other (income) expense, net   (667 )     (415 )   (667 )     (415 )
Provision for income taxes   235       89     235       89  
Depreciation and amortization   1,407       1,416     1,407       1,416  
Stock-based compensation   6,641       2,995     6,641       2,995  
Non-recurring professional fees   169           169        
Severance costs   1,587           1,587        
Adjusted EBITDA $ 4,316     $ 127   $ 4,316     $ 127  
             
             
             
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
(in thousands)
(unaudited)
             
  For the Three Months Ended March 31, For the Years Ended March 31,
    2026       2025     2026       2025  
Loss from continuing operations $ (5,056 )   $ (3,958 ) $ (5,056 )   $ (3,958 )
Product rationalization, tax effected                    
Arbitration settlement, tax effected                    
Stock-based compensation, tax effected   6,965       3,063     6,965       3,063  
Non-recurring professional fees, tax effected   177           177        
Severance costs, tax effected   1,664           1,664        
Adjusted net income (loss) from continuing operations $ 3,750     $ (895 )   3,750     $ (895 )
             
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Operations Per Share
(in thousands, except per share data)
(unaudited)
             
  For the Three Months Ended March 31, For the Years Ended March 31,
    2026       2025     2026       2025  
Diluted loss from continuing operations per share $ (0.37 )   $ (0.28 ) $ (0.37 )   $ (0.28 )
Stock-based compensation, tax effected   0.51       0.22   $ 0.51       0.22  
Non-recurring professional fees, tax effected   0.01       $ 0.01        
Severance costs, tax effected   0.12           0.12        
Costs of shareholder activism, tax effected                    
Adjusted diluted net income (loss) from continuing operations per share $ 0.27     $ (0.06 ) $ 0.27     $ (0.06 )
             
Anika Therapeutics, Inc. and Subsidiaries  
Revenue by Product Family  
(in thousands, except percentages)  
(unaudited)  
                                 
  For the Three Months Ended March 31,   For the Three Months Ended March 31,  
    2026     2025   $ change   % change     2026     2025   $ change   % change  
OEM Channel $ 17,035   $ 14,909   $ 2,126   14 %   $ 17,035   $ 14,909   $ 2,126   14 %  
Commercial Channel   12,577     11,259     1,318   12 %     12,577     11,259     1,318   12 %  
  $ 29,612   $ 26,168   $ 3,444   13 %   $ 29,612   $ 26,168   $ 3,444   13 %  
                                 



Extreme Networks Reports Third Quarter Fiscal Year 2026 Financial Results

Extreme Networks Reports Third Quarter Fiscal Year 2026 Financial Results

Revenue up 11% and SaaS ARR Growth Accelerates to 29% YoY on Extreme Platform ONE Growth

Secured Forward Supply Chain to Meet Demand and Stabilize Gross Margins

MORRISVILLE, N.C.–(BUSINESS WIRE)–
Extreme Networks, Inc. (“Extreme”) (Nasdaq: EXTR) today released financial results for its third quarter of fiscal 2026 ended March 31, 2026.

“Our fifth straight quarter of double-digit growth highlights strong momentum, fueled by disciplined execution, differentiated technology, and rising demand for our AI-powered platform. We’ve fully addressed our current and longer-term supply chain needs, including memory, through targeted sourcing strategies, product redesign, and strategic purchase commitments. These actions position us for continued share gains and growth. This quarter’s results reflect not just our performance today, but the strength and scalability of our strategy going forward,” said Ed Meyercord, President and CEO of Extreme.

“SaaS ARR growth accelerated, reflecting rising adoption and deeper customer engagement with Extreme Platform ONE. This momentum underscores the power of our platform approach and the shift toward a more predictable, recurring revenue model. It’s a clear signal that customers are standardizing on our platform to drive automation, boost productivity, and scale their operations,” said Meyercord.

Kevin Rhodes, Executive Vice President and Chief Financial Officer, noted, “The third quarter marked our eighth consecutive quarter of sequential product revenue growth, reflecting continued execution and share gains. Enterprise networking demand remains resilient, and the targeted pricing actions we implemented are successfully offsetting the incremental supply chain costs we have incurred. Together, these actions underpin our gross margin results and outlook. In addition, we returned $50 million to shareholders through an accelerated share repurchase, underscoring our confidence in the durability of our operating model and cash flow generation.”

Fiscal Third Quarter Results:

  • Revenue $316.9 million, up 11% year-over-year and relatively flat quarter-over-quarter

  • SaaS ARR $236.4 million, up 28.6% year-over-year and 4.2% quarter-over-quarter

  • GAAP diluted EPS $0.08, compared to $0.03 last year and $0.06 last quarter

  • Non-GAAP diluted EPS $0.26, compared to $0.21 last year and $0.26 last quarter

  • GAAP gross margin 61.7%, compared to 61.7% last year and 61.4% last quarter

  • Non-GAAP gross margin 62.3%, compared to 62.3% last year and 62.0% last quarter

  • GAAP operating margin 5.5%, compared to 3.6% last year and 4.1% last quarter

  • Non-GAAP operating margin 15.2%, compared to 14.1% last year and 15.0% last quarter

  • Share repurchases of $50.0 million during the quarter

Liquidity:

  • Q3 ending cash balance was $210.1 million, a decrease of $9.7 million from the end of Q2 2026 and an increase of $24.6 million from the end of Q3 in the prior year.

  • Q3 net cash was $11.3 million, as compared to net cash of $47.3 million at the end of Q2 2026 and net cash of $3.0 million at the end of Q3 in the prior year.

Recent Key Highlights:

  • Extreme supported Lucas Oil Stadium in Indianapolis for the NCAA Men’s Final Four and rapidly modernized connectivity by removing legacy access points and deploying temporary infrastructure to ensure the venue was fully game-ready on an accelerated timeline. With Wi-Fi 7 from Extreme coming in time for the upcoming Indianapolis Colts season, this upgrade will enhance stadium operations through faster, more reliable network performance for ticketing, security, and concessions, while elevating the fan experience with seamless high-speed connectivity for streaming and mobile engagement.

  • Extreme secured several new Extreme Platform ONE wins during the quarter, including Asiana Airlines, Atlantic Food Distributors, Bridgeport Public Schools, City of Prescott (AZ), Johnstone Supply, Nissha Medical Technologies, and the University of Buckingham. These customers are leveraging AI-powered automation to reduce manual tasks, streamline operations, minimize network complexity, and enable faster execution at lower cost.

  • Extreme continues to gain share within the UK National Health Service, with a new win at South London and Maudsley NHS Foundation Trust, where Extreme displaced a larger Chinese competitor. Fabric played a key role by delivering secure segmentation to protect patient data and devices. NHS selected Extreme’s one-license, one-device model for its simplicity and predictable cost.

  • London Business School is deploying a full-stack Extreme solution to modernize networking across a complex urban campus spanning historic and modern academic buildings. The solution includes Extreme Platform ONE and wired and wireless platforms. Using Extreme Fabric, the school is automating and unifying the network across dorms, labs, and academic buildings, simplifying deployment while ensuring consistent security policies. Extreme Platform ONE provides unified management and security, while high-performance Wi-Fi 7 enables secure, seamless connectivity for students, faculty, and staff across campus.
  • Extreme is enhancing the fan experience for the Carolina Hurricanes at the Lenovo Center with a full Wi-Fi 7 upgrade, replacing legacy Wi-Fi 5 to deliver faster, more reliable connectivity throughout the arena.

Fiscal Q3 2026 Financial Results:

(in millions, except percentages and per share information)

 

 

GAAP Results

 

Three Months Ended

 

March 31, 2026

 

March 31, 2025

 

Change

Product

$

199.4

 

$

178.1

 

$

21.3

 

Subscription and support

 

117.5

 

 

106.4

 

 

11.1

 

Total net revenue

$

316.9

 

$

284.5

 

$

32.4

 

Gross margin

 

61.7

%

 

61.7

%

 

0.0

%

Operating margin

 

5.5

%

 

3.6

%

 

1.9

%

Net income

$

10.6

 

$

3.5

 

$

7.1

 

Net income per diluted share

$

0.08

 

$

0.03

 

$

0.05

 

 

Non-GAAP Results

 

Three Months Ended

 

March 31, 2026

 

March 31, 2025

 

Change

Product

$

199.4

 

$

178.1

 

$

21.3

 

Subscription and support

 

117.5

 

 

106.4

 

 

11.1

 

Total net revenue

$

316.9

 

$

284.5

 

$

32.4

 

Gross margin

 

62.3

%

 

62.3

%

 

0.0

%

Operating margin

 

15.2

%

 

14.1

%

 

1.1

%

Net income

$

34.8

 

$

28.0

 

$

6.8

 

Net income per diluted share

$

0.26

 

$

0.21

 

$

0.05

 

Extreme uses the non-GAAP free cash flow metric as a measure of operating performance. Free cash flow represents GAAP net cash provided by operating activities, less purchases of property, equipment and capitalized software development costs. Extreme considers free cash flow to be useful information for management and investors regarding the amount of cash generated by the business after the purchases of property, equipment and capitalized software development costs, which can then be used to, among other things, invest in Extreme’s business, make strategic acquisitions, and strengthen the balance sheet. A limitation of the utility of this non-GAAP free cash flow metric as a measure of financial performance is that it does not represent the total increase or decrease in the Company’s cash balance for the period. The following table shows the non-GAAP free cash flow calculation (in millions):

Free Cash Flow

Three Months Ended

 

March 31, 2026

 

March 31, 2025

Cash flow provided by operations

$

14.2

 

 

$

30.0

 

Less: Capital expenditures for property, equipment and capitalized software development costs

 

(6.4

)

 

 

(5.8

)

Total free cash flow

$

7.8

 

 

$

24.2

 

SaaS ARR: SaaS annual recurring revenue (“SaaS ARR”) represents the annualized value of our subscription offerings and the renewable, term-based license portion of software license arrangements. SaaS ARR excludes perpetual licenses, upfront license fees, variable or non-recurring revenue, professional services revenue, support revenue from maintenance contracts, and other non-subscription revenue. SaaS ARR reflects the annual recurring revenue associated with Extreme Platform ONE (which includes embedded support), ExtremeCloud IQ, and other subscription revenue, based on the annualized value of quarterly subscription revenue and the trailing twelve months of term-based license revenue. Management uses SaaS ARR to evaluate the scale and trajectory of the Company’s subscription-based offerings and progress against customer adoption initiatives. We believe this metric is useful to investors for the same reasons, as it provides insight into our ability to acquire new customers and to maintain and expand our existing customer relationships. SaaS ARR is an operating metric and should be considered independently of revenue or deferred revenue determined in accordance with U.S. GAAP. SaaS ARR does not have a standardized meaning and therefore may not be comparable to similarly titled measures presented by other companies. SaaS ARR is not intended to be a replacement for, or a forecast of, revenue.

Gross debt: Gross debt is defined as long-term debt and the current portion of long-term debt as shown on the balance sheet plus unamortized debt issuance costs, if any.

Net cash: is defined as cash and cash equivalents minus gross debt, as shown in the table below (in millions):

Cash and cash equivalents

 

Gross debt

 

Net cash

$

210.1

 

 

$

198.8

 

 

$

11.3

 

Business Outlook:

Extreme’s business outlook is based on current expectations. The following statements are forward-looking, and actual results could differ materially based on various factors, including market conditions and the factors set forth under “Forward-Looking Statements” below.

For its fourth quarter fiscal 2026, ending June 30, 2026, the Company is targeting:

(in millions, except percentages and per share information)

 

Low-End

 

High-End

FQ4’26 Guidance – GAAP

 

 

 

 

 

Total net revenue

$

330.0

 

 

$

335.0

 

Gross margin

 

61.2

%

 

 

61.6

%

Operating margin

 

6.1

%

 

 

7.1

%

Earnings per share

$

0.12

 

 

$

0.15

 

Diluted shares outstanding used in calculating GAAP EPS

 

131.8

 

 

 

131.8

 

FQ4’26 Guidance – Non-GAAP

 

 

 

 

 

Total net revenue

$

330.0

 

 

$

335.0

 

Gross margin

 

61.8

%

 

 

62.2

%

Operating margin

 

15.2

%

 

 

16.1

%

Earnings per share

$

0.28

 

 

$

0.30

 

Diluted shares outstanding used in calculating non-GAAP EPS

 

131.8

 

 

 

131.8

 

The following table shows the GAAP to non-GAAP reconciliation for Q4 FY’26 guidance:

 

FQ4’26

 

Gross Margin

 

Operating Margin

 

Earnings per Share

GAAP

61.2% – 61.6%

 

6.1% – 7.1%

 

$0.12 – $0.15

Estimated adjustments for:

 

 

 

 

 

Share-based compensation

0.5%

 

7.0% – 7.1%

 

0.18

Amortization of product intangibles

0.1%

 

0.1%

 

0.00

Amortization of non-product intangibles

 

0.1%

 

0.00

Litigation charges

 

0.9%

 

0.02

System transition costs

 

0.9%

 

0.02

Tax adjustment

 

 

(0.07) – (0.06)

Non-GAAP

61.8% – 62.2%

 

15.2% – 16.1%

 

$0.28 – $0.30

The total percentage rate changes may not equal the total change in all cases due to rounding.

For the full year fiscal 2026, ending June 30, 2026, the Company is targeting:

(in millions, except percentages and per share information)

Low-End

 

High-End

FY’26 Guidance

 

 

 

 

 

Total net revenue

$

1,275.0

 

 

$

1,280.0

 

Gross margin

 

61.2

%

 

 

61.3

%

Operating margin

 

4.8

%

 

 

5.1

%

Earnings per share

$

0.30

 

 

$

0.33

 

Diluted shares outstanding used in calculating GAAP EPS

 

133.9

 

 

 

133.9

 

FY’26 Guidance – Non-GAAP

 

 

 

 

 

Total net revenue

$

1,275.0

 

 

$

1,280.0

 

Gross margin

 

61.8

%

 

 

61.9

%

Operating margin

 

14.7

%

 

 

14.9

%

Earnings per share

$

1.02

 

 

$

1.04

 

Diluted shares outstanding used in calculating non-GAAP EPS

 

133.9

 

 

 

133.9

 

The following table shows the GAAP to non-GAAP reconciliation for FY’26 guidance:

 

FY’26

 

Gross Margin

 

Operating Margin

 

Earnings per Share

GAAP

61.2% – 61.3%

 

4.8% – 5.1%

 

$0.30 – $0.33

Estimated adjustments for:

 

 

 

 

 

Share-based compensation

0.5%

 

7.1% – 7.2%

 

0.67

Amortization of product intangibles

0.1%

 

0.1%

 

0.01

Amortization of non-product intangibles

 

0.1%

 

0.01

Other non-recurring costs

 

0.3%

 

0.03

Litigation charges

 

0.5%

 

0.05

System transition costs

 

1.7%

 

0.16

Tax adjustment

 

 

(0.22) – (0.21)

Non-GAAP

61.8% – 61.9%

 

14.7% – 14.9%

 

$1.02 – $1.04

The total percentage rate changes may not equal the total change in all cases due to rounding.

Conference Call:

Extreme will host a conference call at 8:00 a.m. Eastern (5:00 a.m. Pacific) today to review the third quarter results of fiscal 2026 as well as the business outlook for the fourth quarter of fiscal 2026 and the full year fiscal 2026, ending June 30, 2026, including significant factors and assumptions underlying the targets noted above. The conference call will be available to the public through a live audio web broadcast via the internet at http://investor.extremenetworks.com and a replay of the call will be available on the website for at least 7 days following the call. To access the call, please go to this link (Registration Link) and you will be provided with dial in details. If you would like to participate in the Q&A, please register here: Q&A Registration Link. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

About Extreme:

Extreme Networks, Inc. (EXTR) is a leader in AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. We push the boundaries of technology, leveraging the powers of artificial intelligence, analytics, and automation. Tens of thousands of customers globally trust our AI-driven cloud networking solutions and industry-leading support to enable businesses to drive value, foster innovation, and overcome extreme challenges. For more information, visit Extreme’s website at https://www.extremenetworks.com/ or LinkedIn, YouTube, X (Formerly Twitter), Facebook or Instagram.

Extreme Networks, ExtremeCloud, Extreme Platform ONE, and the Extreme Networks logo, are trademarks of Extreme Networks, Inc. or its subsidiaries in the United States and/or other countries. Other trademarks shown herein are the property of their respective owners.

Non-GAAP Financial Measures:

Extreme provides all financial information required in accordance with U.S. generally accepted accounting principles (“GAAP”). The Company is providing with this press release non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income per diluted share, adjusted EBITDA, net cash and free cash flow. In preparing non-GAAP information, the Company has excluded, where applicable, the impact of share-based compensation, amortization of intangibles, restructuring and related charges, system transition costs, litigation charges, other non-recurring costs, debt refinancing charges and the tax effect of non-GAAP adjustments. The Company believes that excluding these items provides both management and investors with additional insight into its current operations, the trends affecting the Company, the Company’s marketplace performance, and the Company’s ability to generate cash from operations. Please note the Company’s non-GAAP measures may be different than those used by other companies. The additional non-GAAP financial information the Company presents should be considered in conjunction with, and not as a substitute for, the Company’s GAAP financial information.

The Company has provided a non-GAAP reconciliation of the results for the periods presented in this release, which are adjusted to exclude certain items as indicated. These measures should only be used to evaluate the Company’s results of operations in conjunction with the corresponding GAAP measures for comparable financial information and understanding of the Company’s ongoing performance as a business. Extreme uses both GAAP and non-GAAP measures to evaluate and manage its operations.

Forward-Looking Statements:

This press release contains ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding our outlook, targets, and guidance; our expectations regarding demand, product adoption, competitive dynamics, revenues, margins, cash flow and other operating or financial results; and our plans, objectives and assumptions. These forward-looking statements speak only as of the date of this release. There are several important factors that could cause actual results and other future events to differ materially from those suggested or indicated by such forward-looking statements. These include, among others, risks related to global macroeconomic, industry and business trends; variability in demand, sales cycles and pipeline conversion; the Company’s failure to achieve targeted financial metrics; a highly competitive business environment for network switching equipment and cloud management of network devices; supply chain challenges and component shortages; the Company’s effectiveness in controlling expenses; the possibility that the Company might experience delays in the development or introduction of new technology and products; customer response to the Company’s new technology and products; risks related to pending or future litigation; political and geopolitical factors, including the possible impact of tariffs and changes to U.S. tax regulations; and a dependency on third parties for certain components and for the manufacturing of the Company’s products.

For more information about factors that could cause actual results and other future events to differ materially from those suggested or indicated by such forward-looking statements, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents of the Company on file with the Securities and Exchange Commission (available at www.sec.gov). As a result of these risks and others, actual results could vary significantly from those anticipated in this press release, and the Company’s financial condition and results of operations could be materially adversely affected. Except as required under the U.S. federal securities laws and the rules and regulations of the Securities and Exchange Commission, Extreme disclaims any obligation to update any forward-looking statements after the date of this release, whether as a result of new information, future events, developments, changes in assumptions or otherwise.

 

EXTREME NETWORKS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

March 31, 2026

 

June 30, 2025

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

$

210,113

 

$

231,745

 

Accounts receivable, net

 

162,710

 

 

126,708

 

Inventories

 

76,634

 

 

102,578

 

Prepaid expenses and other current assets

 

92,345

 

 

74,265

 

Total current assets

 

541,802

 

 

535,296

 

Property and equipment, net

 

53,544

 

 

44,366

 

Operating lease right-of-use assets, net

 

32,508

 

 

38,655

 

Goodwill

 

398,211

 

 

399,574

 

Intangible assets, net

 

3,840

 

 

6,541

 

Other assets

 

140,155

 

 

128,786

 

Total assets

$

1,170,060

 

$

1,153,218

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

$

81,157

 

$

63,939

 

Accrued compensation and benefits

 

48,669

 

 

62,895

 

Accrued warranty

 

10,139

 

 

9,684

 

Current portion of deferred revenue

 

334,598

 

 

325,078

 

Current portion of long-term debt, net of unamortized debt issuance costs of $679 and $729, respectively

 

48,071

 

 

14,271

 

Current portion of operating lease liabilities

 

12,275

 

 

11,456

 

Other accrued liabilities

 

58,356

 

 

100,552

 

Total current liabilities

 

593,265

 

 

587,875

 

Deferred revenue, less current portion

 

312,515

 

 

292,415

 

Long-term debt, less current portion, net of unamortized debt issuance costs of $777 and $1,276, respectively

 

149,223

 

 

163,724

 

Operating lease liabilities, less current portion

 

26,170

 

 

33,991

 

Deferred income taxes

 

7,343

 

 

7,033

 

Other long-term liabilities

 

2,579

 

 

2,596

 

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Convertible preferred stock, $0.001 par value, issuable in series, 2,000 shares authorized; none issued

 

 

 

 

Common stock, $0.001 par value, 750,000 shares authorized; 156,657 and 152,673 shares issued, respectively; 132,513 and 132,064 shares outstanding, respectively

 

157

 

 

153

 

Additional paid-in capital

 

1,350,759

 

 

1,298,791

 

Accumulated other comprehensive loss

 

(15,684

)

 

(8,137

)

Accumulated deficit

 

(925,352

)

 

(949,429

)

Treasury stock at cost, 24,144 shares and 20,609 shares, respectively

 

(330,915

)

 

(275,794

)

Total stockholders’ equity

 

78,965

 

 

65,584

 

Total liabilities and stockholders’ equity

$

1,170,060

 

$

1,153,218

 

 

EXTREME NETWORKS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

March 31,

2026

 

March 31,

2025

 

March 31,

2026

 

March 31,

2025

Net revenues:

 

 

 

 

 

 

 

 

Product

$

199,345

 

$

178,060

 

$

591,151

 

$

512,605

 

Subscription and support

 

117,529

 

 

106,445

 

 

353,893

 

 

320,459

 

Total net revenues

 

316,874

 

 

284,505

 

 

945,044

 

 

833,064

 

Cost of revenues:

 

 

 

 

 

 

 

 

Product

 

86,206

 

 

76,059

 

 

259,334

 

 

218,065

 

Subscription and support

 

35,124

 

 

33,037

 

 

107,057

 

 

94,960

 

Total cost of revenues

 

121,330

 

 

109,096

 

 

366,391

 

 

313,025

 

Gross profit:

 

 

 

 

 

 

 

 

Product

 

113,139

 

 

102,001

 

 

331,817

 

 

294,540

 

Subscription and support

 

82,405

 

 

73,408

 

 

246,836

 

 

225,499

 

Total gross profit

 

195,544

 

 

175,409

 

 

578,653

 

 

520,039

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

59,184

 

 

55,656

 

 

174,459

 

 

164,990

 

Sales and marketing

 

88,979

 

 

79,773

 

 

267,295

 

 

241,123

 

General and administrative

 

29,634

 

 

29,537

 

 

93,420

 

 

92,202

 

Restructuring and related charges (benefit)

 

 

 

(441

)

 

538

 

 

1,871

 

Amortization of intangible assets

 

407

 

 

507

 

 

1,314

 

 

1,528

 

Total operating expenses

 

178,204

 

 

165,032

 

 

537,026

 

 

501,714

 

Operating income

 

17,340

 

 

10,377

 

 

41,627

 

 

18,325

 

Interest income

 

983

 

 

972

 

 

3,312

 

 

2,657

 

Interest expense

 

(3,249

)

 

(3,797

)

 

(10,262

)

 

(12,398

)

Other expense, net

 

(263

)

 

(385

)

 

(1,110

)

 

(445

)

Income before income taxes

 

14,811

 

 

7,167

 

 

33,567

 

 

8,139

 

Provision for income taxes

 

4,221

 

 

3,709

 

 

9,490

 

 

7,803

 

Net income

$

10,590

 

$

3,458

 

$

24,077

 

$

336

 

 

 

 

 

 

 

 

 

 

Basic and diluted income per share:

 

 

 

 

 

 

 

 

Net income per share – basic

$

0.08

 

$

0.03

 

$

0.18

 

$

0.00

 

Net income per share – diluted

$

0.08

 

$

0.03

 

$

0.18

 

$

0.00

 

 

 

 

 

 

 

 

 

 

Shares used in per share calculation – basic

 

132,931

 

 

132,979

 

 

133,275

 

 

132,173

 

Shares used in per share calculation – diluted

 

133,591

 

 

134,590

 

 

134,917

 

 

133,770

 

 

EXTREME NETWORKS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

 

 

Nine Months Ended

 

 

March 31, 2026

 

March 31, 2025

Cash flows from operating activities:

 

 

 

 

Net income

$

24,077

 

$

336

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation

 

11,600

 

 

11,261

 

Amortization of intangible assets

 

2,631

 

 

3,356

 

Amortization of cloud computing implementation costs

 

2,848

 

 

 

Reduction in carrying amount of right-of-use asset

 

7,710

 

 

7,386

 

Provision for credit losses

 

430

 

 

85

 

Share-based compensation

 

66,447

 

 

61,573

 

Deferred income taxes

 

658

 

 

(879

)

Provision for excess and obsolete inventory

 

4,639

 

 

1,616

 

Non-cash interest expense

 

907

 

 

902

 

Other

 

1,393

 

 

703

 

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable, net

 

(36,432

)

 

(10,113

)

Inventories

 

19,012

 

 

14,445

 

Prepaid expenses and other assets

 

(38,488

)

 

(20,331

)

Accounts payable

 

16,388

 

 

(3,982

)

Accrued compensation and benefits

 

(15,927

)

 

1,302

 

Operating lease liabilities

 

(8,532

)

 

(8,060

)

Deferred revenue

 

33,299

 

 

17,746

 

Other current and long-term liabilities

 

(42,327

)

 

(7,254

)

Net cash provided by operating activities

 

50,333

 

 

70,092

 

Cash flows from investing activities:

 

 

 

 

Capital expenditures for property, equipment and capitalized software development costs

 

(20,364

)

 

(18,067

)

Net cash used in investing activities

 

(20,364

)

 

(18,067

)

Cash flows from financing activities:

 

 

 

 

Borrowings under revolving facility

 

55,000

 

 

 

Payments on revolving facility

 

(25,000

)

 

 

Payments on debt obligations

 

(11,250

)

 

(7,500

)

Payments on debt financing costs

 

 

 

(695

)

Repurchase of common stock including accelerated share repurchases

 

(62,000

)

 

(13,000

)

Payments for tax withholdings, net of proceeds from issuance of common stock

 

(7,596

)

 

(1,907

)

Net cash used in financing activities

 

(50,846

)

 

(23,102

)

Foreign currency effect on cash and cash equivalents

 

(755

)

 

(142

)

Net increase (decrease) in cash and cash equivalents

 

(21,632

)

 

28,781

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

231,745

 

 

156,699

 

Cash and cash equivalents at end of period

$

210,113

 

$

185,480

 

Extreme Networks, Inc.

Non-GAAP Measures of Financial Performance

To supplement the Company’s consolidated financial statements presented in accordance with U.S. generally accepted accounting principles (“GAAP”), Extreme uses non-GAAP measures of certain components of financial performance. These non-GAAP measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income per diluted share, adjusted EBITDA (calculated as GAAP net income excluding interest, income taxes, depreciation and amortization as well as costs or benefits that are not reflective of the Company’s ongoing or expected future operational performance as noted below), net cash and free cash flow.

Reconciliation to the nearest GAAP measure of all historical non-GAAP measures included in this press release can be found in the tables included with this press release.

Non-GAAP measures presented in this press release are not in accordance with or alternative measures prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Extreme’s results of operations as determined in accordance with GAAP. These non-GAAP measures should only be used to evaluate Extreme’s results of operations in conjunction with the corresponding GAAP measures.

Extreme believes these non-GAAP measures, when shown in conjunction with the corresponding GAAP measures, enhance investors’ and management’s overall understanding of the Company’s current financial performance and the Company’s prospects for the future, including cash flows available to pursue opportunities to enhance stockholder value. In addition, because Extreme has historically reported certain non-GAAP results to investors, the Company believes the inclusion of non-GAAP measures provides consistency in the Company’s financial reporting.

For its internal planning process, and as discussed further below, Extreme’s management uses financial statements that do not include share-based compensation expense, amortization of intangibles, restructuring and related charges, system transition costs, litigation charges, other non-recurring costs, debt refinancing charges, and the tax effect of non-GAAP adjustments. Extreme’s management also uses non-GAAP measures, in addition to the corresponding GAAP measures, in reviewing the Company’s financial results.

As described above, Extreme excludes the following items from one or more of its non-GAAP measures when applicable.

Share-based compensation. Share-based compensation consists of associated expenses for stock options, restricted stock awards and the Company’s Employee Stock Purchase Plan. Extreme excludes share-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing cash requirement related to its operating results. Extreme expects to incur share-based compensation expenses in future periods.

Amortization of intangibles. Amortization of intangibles includes the monthly amortization expense of intangible assets such as developed technology, customer relationships and trademarks. The amortization of the developed technology are recorded in cost of goods sold, while the amortization for the other intangibles are recorded in operating expenses. Extreme excludes these expenses since they result from an intangible asset and for which the period expense does not impact the operations of the business and are non-cash in nature.

Restructuring and related charges.Restructuring and related charges consist of severance costs for employees, asset disposal costs and other charges related to excess facilities that do not provide economic benefit to our future operations. Extreme excludes restructuring expenses since they result from events that occur outside of the ordinary course of continuing operations.

System transition costs. System transition costs consist of costs related to direct and incremental costs incurred in connection with our multi-phase transition of our customer relationship management solution, our configure, price, quote solution and our enterprise resource planning tools that were not capitalizable. Extreme excludes these costs because we believe that these costs do not reflect future operating expenses and will be inconsistent in amount and frequency, making it difficult to contribute to a meaningful evaluation of our operating performance.

Litigation charges. Litigation charges consist of estimated settlement and related legal expenses for non-recurring litigations offset by any proceeds received or expected to be received from insurance.

Debt refinancing charges. Debt refinancing charges consist of costs that were not capitalizable and are included in other expense, net, that occurred in conjunction with the amendments related to our outstanding credit facility.

Other non-recurring costs. Other non-recurring costs consist of certain external advisory and professional fees incurred for various non-recurring transactions and activities that occur outside of the normal course of business. Extreme excludes these costs because we believe that these costs do not reflect future operating expenses and will be inconsistent in amount and frequency, making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax effect of non-GAAP adjustments. We calculate our non-GAAP provision for income taxes in accordance with the SEC guidance on non-GAAP Financial Measures Compliance and Disclosure Interpretation. We have assumed our U.S. federal and state net operating losses would have been fully consumed by the historical non-GAAP financial adjustments, eliminating the need for a full valuation allowance against our U.S. deferred tax assets which, consequently, enables our use of research and development tax credits. The non-GAAP tax provision consists of current and deferred income tax expense commensurate with the non-GAAP measure of profitability using our blended U.S. statutory tax rate of 24.6%.

The non-GAAP provision for income taxes has typically been and is currently higher than the GAAP provision given the Company has a valuation allowance against its US and a portion of its Irish deferred tax assets due to historical losses. Once these valuation allowances are released, the non-GAAP and the GAAP provision for income taxes will be more closely aligned.

Over the next year, our cash taxes will be driven by US federal and state taxes and the tax expense of our foreign subsidiaries, which amounts have not historically been significant, with the exception of the Company’s Canadian, German and Indian subsidiaries which perform research and development and sales and marketing activities for the Company, as well as the Company’s Irish trading subsidiaries.

EXTREME NETWORKS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

(In thousands, except percentages and per share amounts)

(Unaudited)

 

Revenues

Three Months Ended

 

Nine Months Ended

 

March 31,

2026

 

March 31,

2025

 

March 31,

2026

 

March 31,

2025

Revenues – GAAP

$

316,874

 

$

284,505

 

$

945,044

 

$

833,064

 

Non-GAAP Gross Margin

Three Months Ended

Nine Months Ended

 

March 31,

2026

March 31,

2025

March 31,

2026

March 31,

2025

Gross profit – GAAP

$

195,544

 

$

175,409

 

$

578,653

 

$

520,039

 

Gross margin – GAAP percentage

 

61.7

%

 

61.7

%

 

61.2

%

 

62.4

%

Adjustments:

 

 

 

 

 

 

 

 

Share-based compensation expense, Product

 

755

 

 

663

 

 

2,303

 

 

1,961

 

Share-based compensation expense, Subscription and support

 

723

 

 

706

 

 

2,209

 

 

2,193

 

Amortization of intangibles, Product

 

336

 

 

580

 

 

1,264

 

 

1,775

 

Total adjustments to GAAP gross profit

$

1,814

 

$

1,949

 

$

5,776

 

$

5,929

 

Gross profit – non-GAAP

$

197,358

 

$

177,358

 

$

584,429

 

$

525,968

 

Gross margin – non-GAAP percentage

 

62.3

%

 

62.3

%

 

61.8

%

 

63.1

%

Non-GAAP Operating Margin

Three Months Ended

Nine Months Ended

 

March 31,

2026

March 31,

2025

March 31,

2026

March 31,

2025

GAAP operating income

$

17,340

 

$

10,377

 

$

41,627

 

$

18,325

 

GAAP operating margin

 

5.5

%

 

3.6

%

 

4.4

%

 

2.2

%

Adjustments:

 

 

 

 

 

 

 

 

Share-based compensation expense, cost of revenues

 

1,478

 

 

1,369

 

 

4,512

 

 

4,154

 

Share-based compensation expense, R&D

 

4,267

 

 

4,178

 

 

13,353

 

 

12,858

 

Share-based compensation expense, S&M

 

7,564

 

 

6,963

 

 

23,086

 

 

21,441

 

Share-based compensation expense, G&A

 

8,459

 

 

7,844

 

 

25,496

 

 

23,120

 

Restructuring and related charges (benefit)

 

 

 

(441

)

 

538

 

 

1,871

 

Litigation charges

 

376

 

 

1,123

 

 

3,135

 

 

12,716

 

System transition costs

 

7,556

 

 

7,548

 

 

18,948

 

 

16,919

 

Amortization of intangibles

 

743

 

 

1,087

 

 

2,578

 

 

3,303

 

Other non-recurring costs

 

231

 

 

 

 

3,879

 

 

 

Total adjustments to GAAP operating income

$

30,674

 

$

29,671

 

$

95,525

 

$

96,382

 

Non-GAAP operating income

$

48,014

 

$

40,048

 

$

137,152

 

$

114,707

 

Non-GAAP operating margin

 

15.2

%

 

14.1

%

 

14.5

%

 

13.8

%

 

 

 

 

 

 

 

 

 

Non-GAAP Net Income

Three Months Ended

 

Nine Months Ended

 

March 31,

2026

 

March 31,

2025

 

March 31,

2026

 

March 31,

2025

GAAP net income

$

10,590

 

$

3,458

 

$

24,077

 

$

336

 

Adjustments:

 

 

 

 

 

 

 

 

Share-based compensation expense

 

21,768

 

 

20,354

 

 

66,447

 

 

61,573

 

Restructuring and related charges (benefit)

 

 

 

(441

)

 

538

 

 

1,871

 

Litigation charges

 

376

 

 

1,123

 

 

3,135

 

 

12,716

 

System transition costs

 

7,556

 

 

7,548

 

 

18,948

 

 

16,919

 

Amortization of intangibles

 

743

 

 

1,087

 

 

2,578

 

 

3,303

 

Other non-recurring costs

 

231

 

 

 

 

3,879

 

 

 

Debt refinancing charges

 

 

 

 

 

 

 

79

 

Tax effect of non-GAAP adjustments

 

(6,419

)

 

(5,171

)

 

(19,888

)

 

(17,866

)

Total non-GAAP adjustments to GAAP net income

$

24,255

 

$

24,500

 

$

75,637

 

$

78,595

 

Non-GAAP net income

$

34,845

 

$

27,958

 

$

99,714

 

$

78,931

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

 

 

 

 

GAAP net income per share – diluted

$

0.08

 

$

0.03

 

$

0.18

 

$

0.00

 

Non-GAAP net income per share – diluted

$

0.26

 

$

0.21

 

$

0.74

 

$

0.59

 

 

 

 

 

 

 

 

 

 

Shares used in net income per share – diluted:

 

 

 

 

 

 

 

 

GAAP shares used in per share calculation – basic

 

132,931

 

 

132,979

 

 

133,275

 

 

132,173

 

Potentially dilutive equity awards

 

660

 

 

1,611

 

 

1,642

 

 

1,597

 

GAAP and Non-GAAP shares used in per share calculation – diluted

 

133,591

 

 

134,590

 

 

134,917

 

 

133,770

 

Adjusted EBITDA

Three Months Ended

Nine Months Ended

 

March 31,

2026

March 31,

2025

March 31,

2026

March 31,

2025

GAAP net income

$

10,590

 

$

3,458

 

$

24,077

 

$

336

 

Adjustments:

 

 

 

 

 

 

 

 

Depreciation expense

 

3,807

 

 

3,456

 

 

11,600

 

 

11,261

 

Amortization expense

 

2,584

 

 

1,105

 

 

5,479

 

 

3,356

 

Share-based compensation expense

 

21,768

 

 

20,354

 

 

66,447

 

 

61,573

 

Restructuring and related charges (benefit)

 

 

 

(441

)

 

538

 

 

1,871

 

Litigation charges

 

376

 

 

1,123

 

 

3,135

 

 

12,716

 

System transition costs

 

7,556

 

 

7,548

 

 

18,948

 

 

16,919

 

Other non-recurring costs

 

231

 

 

 

 

3,879

 

 

 

Debt refinancing charges

 

 

 

 

 

 

 

79

 

Interest income

 

(983

)

 

(972

)

 

(3,312

)

 

(2,657

)

Interest expense

 

3,249

 

 

3,797

 

 

10,262

 

 

12,398

 

Provision for income taxes

 

4,221

 

 

3,709

 

 

9,490

 

 

7,803

 

Total adjustments to GAAP net income

 

42,809

 

 

39,679

 

 

126,466

 

 

125,319

 

Adjusted EBITDA

$

53,399

 

$

43,137

 

$

150,543

 

$

125,655

 

 

Investor Relations

Stan Kovler

919/595-4196

[email protected]

Media Contact

Amy Aylward

603/952-5138

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Mobile/Wireless Technology Security Telecommunications Software Networks Internet Hardware Data Management Artificial Intelligence

MEDIA:

Logo
Logo

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 4973685
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available on the Ocugen investor site.

About Ocugen, Inc.

Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
[email protected] 



Hayward Holdings Reports First Quarter Fiscal Year 2026 Financial Results and Increases Guidance

Hayward Holdings Reports First Quarter Fiscal Year 2026 Financial Results and Increases Guidance

FIRST QUARTER FISCAL 2026 SUMMARY

  • Net Sales increased 12% year-over-year to $255.2 million

  • Net Income increased 63% year-over-year to $23.4 million

  • Adjusted EBITDA* increased 15% year-over-year to $56.4 million

  • Diluted earnings per share (EPS) increased 83% year-over-year to $0.11

  • Adjusted diluted EPS* increased 30% year-over-year to $0.13

CHARLOTTE, N.C.–(BUSINESS WIRE)–
Hayward Holdings, Inc. (NYSE: HAYW) (“Hayward,” the “Company,” “we,” “us,” or “our”), a leading global specialty water management company focused on designing and manufacturing pool and outdoor living technology and industrial flow control products, today announced financial results for the first quarter of fiscal year 2026, ended March 28, 2026. Comparisons are to financial results for the prior-year first fiscal quarter.

CEO COMMENTS

“Hayward delivered an outstanding first quarter highlighted by double-digit net sales growth and increased profitability,” said Kevin Holleran, Hayward’s President and Chief Executive Officer. “Net sales increased 12% year-over-year, primarily driven by further strong price realization and positive volume growth, underscoring the strength of our predominantly installed base aftermarket business model and disciplined execution of our strategic initiatives. We achieved another quarter of margin expansion while making targeted investments in new product innovation and customer service. Based on our strong start to the year, we are increasing our full year guidance and remain confident in our ability to deliver continued profitable growth and stockholder value.”

FIRST QUARTER FISCAL 2026 CONSOLIDATED RESULTS

Net sales increased by 12% to $255.2 million for the first quarter of fiscal 2026. The increase in net sales during the quarter was driven by positive net price to offset inflation and tariffs, the favorable impact from foreign currency translation, and an increase in volume.

Gross profit increased by 13% to $118.7 million for the first quarter of fiscal 2026. Gross profit margin increased by 50 basis points to 46.5% primarily due to positive net price and operating efficiencies, partially offset by an increase in cost of sales driven by tariffs and inflation.

Selling, general, and administrative expense (“SG&A”) increased by 10% to $62.6 million for the first quarter of fiscal 2026. The increase in SG&A was mainly attributable to the timing of certain sales expenses during the year, incremental advertising expense for trade shows and new customers, and increased software costs. As a percentage of net sales, SG&A decreased to 24.5% for the first quarter of fiscal 2026 as compared to 24.9% in the prior-year period, a decrease of 40 basis points, as the growth in net sales exceeded the growth in SG&A.

Research, development, and engineering expense (“RD&E”) increased by 13% to $6.8 million for the first quarter of fiscal 2026. The increase was primarily driven by investments in new product development and new product performance improvements. As a percentage of net sales, RD&E remained relatively consistent as 2.6% for both the first quarters of fiscal 2026 and 2025.

Operating income increased by 27% to $42.5 million for the first quarter of fiscal 2026, due to the aggregated effects of the items described above. Operating income as a percentage of net sales was 16.6% for the first quarter of fiscal 2026, a 200 basis point increase compared to 14.6% in the prior-year period.

Interest expense, net, decreased by 16% to $11.5 million for the first quarter of fiscal 2026, primarily due to higher interest income on cash deposits and decreased net interest expense on bank debt.

Net income increased by 63% to $23.4 million for the first quarter of fiscal 2026. Net income margin increased by 290 basis points to 9.2%. Adjusted net income* increased by 35% to $29.8 million for the first quarter of fiscal 2026. Adjusted net income margin* increased by 200 basis points to 11.7%.

Adjusted EBITDA* increased by 15% to $56.4 million for the first quarter of fiscal 2026 compared to $49.1 million in the prior-year period. Adjusted EBITDA margin* increased by 60 basis points to 22.1%.

Diluted EPS increased by 83% to $0.11 for the first quarter of fiscal 2026. Adjusted diluted EPS* increased by 30% to $0.13 for the first quarter of fiscal 2026.

FIRST QUARTER FISCAL 2026 SEGMENT RESULTS

North America (NAM)

Net sales increased by 12% to $209.8 million for the first quarter of fiscal 2026. The increase was driven by positive net price to offset inflation and tariffs, an increase in volume, and the favorable impact from foreign currency translation.

Segment income increased by 16% to $50.5 million for the first quarter of fiscal 2026. Adjusted segment income* increased by 13% to $57.3 million.

Europe & Rest of World (E&RW)

Net sales increased by 9% to $45.4 million for the first quarter of fiscal 2026. The increase was primarily due to the favorable impact of foreign currency translation and positive net price, partially offset by a modest decrease in volume.

Segment income increased by 27% to $8.3 million for the first quarter of fiscal 2026. Adjusted segment income* increased by 26% to $8.8 million.

BALANCE SHEET AND CASH FLOW

As of March 28, 2026, Hayward had cash and cash equivalents of $135.8 million, short-term investments of $94.9 million and $186.6 million available for future borrowings under its revolving credit facilities. Net cash used in operating activities for the three months ended March 28, 2026 increased by $144.8 million from the three months ended March 29, 2025. The increase in cash used was primarily driven by higher accounts receivable, largely because there were no sales under the Receivables Purchase Agreement in the current period, whereas the prior year period included the sale of $100.0 million of accounts receivable.

OUTLOOK

Hayward is increasing its full year 2026 guidance reflecting continued sales and earnings growth driven by solid execution across the organization, positive price realization and continued technology adoption. For Fiscal Year 2026, Hayward now expects net sales to increase approximately 5% from Fiscal Year 2025, compared to our prior guidance of approximately 4%. We now expect adjusted diluted earnings per share* of $0.84 to $0.87, an increase of approximately 9% to 13% from Fiscal Year 2025, compared to our prior guidance of $0.82 to $0.86.

Hayward is excited about the long-term dynamics of the pool industry. The installed base of pools increases every year, providing continued growth opportunities, and the Company benefits from favorable secular demand trends in outdoor living, sunbelt migration, and technology adoption. Hayward continues to leverage its competitive advantages and drive increasing adoption of its leading SmartPad™ pool equipment products both in new construction and the aftermarket, which represents approximately 85% of net sales. Hayward is confident in its long-term outlook for profitable growth and robust cash flow generation, driven by its technology leadership, operational excellence, strong brand and installed base, and multi-channel capabilities.

Please see the Forward-Looking Statements section of this release for a discussion of certain risks relevant to Hayward’s outlook.

CONFERENCE CALL INFORMATION

Hayward will hold a conference call to discuss the results today, April 29, 2026 at 9:00 a.m. (ET).

Interested investors and other parties can listen to a webcast of the live conference call by logging on to the Investor Relations section of the Company’s website at https://investor.hayward.com/events-and-presentations/default.aspx. An earnings presentation will be posted to the Investor Relations section of the Company’s website prior to the conference call.

The conference call can also be accessed by dialing (877) 423-9813 or (201) 689-8573.

For those unable to listen to the live conference call, a replay will be available approximately three hours after the call through the archived webcast on the Hayward website or by dialing (844) 512-2921 or (412) 317-6671. The access code for the replay is 13759829. The replay will be available until 11:59 p.m. Eastern Time on May 13, 2026.

ABOUT HAYWARD HOLDINGS, INC.

Hayward Holdings, Inc. (NYSE: HAYW) is a leading global specialty water management company focused on designing and manufacturing pool and outdoor living technology and industrial flow control products. Driven by a mission to transform the experience of water, Hayward offers a comprehensive portfolio of energy‑efficient and sustainable pool equipment—including pumps, heaters, sanitizers, filters, LED lighting, water features, and cleaners—integrated through its intuitive, IoT‑enabled SmartPad™ platform. The Company also provides industrial thermoplastic valves and process control products serving a wide range of applications.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This earnings release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) and rules and regulations of the Securities and Exchange Commission (“SEC”). Forward-looking statements include, without limitation, statements regarding our plans, strategies, objectives, expectations, intentions, outlook, expenditures, guidance, targets, and assumptions, as well as other statements that are not historical facts. Forward-looking statements are based on management’s current beliefs, assumptions, expectations, and information available at the time the statements are made. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements are made in reliance upon the safe harbor provisions of the Act. However, forward-looking statements are subject to risks, uncertainties, and other factors, many of which are beyond our control, that could cause actual results to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to publicly update, revise, or correct any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable federal securities laws. Forward-looking statements should be read in conjunction with the risk factors and other cautionary statements, including those described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and other filings with the SEC.

Important factors that could cause actual results to differ materially include, but are not limited to, the following:

  • our business depends on the performance of distributors, builders, buying groups, retailers and servicers;

  • the demand for our products may be adversely affected by unfavorable economic and business conditions;

  • we operate in markets with high levels of competition;

  • our future success depends on developing, manufacturing and attaining market adoption of new products and maintaining product quality and reliability;

  • our ability to keep pace with rapidly evolving technological developments and standards, including artificial intelligence , and effectively develop and deploy such technologies;

  • our results of operations and cash flows may fluctuate from quarter to quarter;

  • a loss of, or material cancellation, reduction or delay in purchases by one or more of our largest customers;

  • our exposure to credit risk on our accounts receivable;

  • risks arising from our international business operations;

  • past growth may not be indicative of future growth;

  • our inability to identify, finance and complete suitable acquisitions;

  • negative impacts of litigation and other claims;

  • future impairment of our goodwill and intangible assets;

  • exchange rate fluctuations, cost increases and other inflation, changes in our effective tax rate or exposure to additional income tax liabilities;

  • our ability to attract, develop and retain highly qualified personnel, including key members of management;

  • disruptions in the financial markets;

  • significant disruption or breach of our technology infrastructure or that of our vendors or third parties, or failure to maintain the security of confidential information;

  • difficulties in operating or implementing the new ERP system or human resources information system;

  • misuse of our technology-enabled products;

  • failure to maintain an effective system of internal controls;

  • dependence on key suppliers, including single-source suppliers and sole-source suppliers;

  • ability to manage product inventory in an effective and efficient manner;

  • product manufacturing disruptions, including as a result of catastrophic or other events beyond our control;

  • tariffs and other trade restrictions and the cost of raw materials;

  • compliance with, and potential liabilities under, employment, environmental, health, transportation, safety and other governmental laws and regulations;

  • risks related to our handling of personal information;

  • our employees, commercial partners and vendors may engage in misconduct or other improper activities;

  • violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other anti-corruption laws;

  • our failure to comply with international trade compliance regulations, and changes in U.S. government sanctions;

  • changes in laws, regulations, government policies or regulatory interpretations;

  • climate change and legal or regulatory responses thereto, and increasing scrutiny from stakeholders on environmental, social and other sustainability matters;

  • our ability to obtain, maintain and enforce our intellectual property and proprietary rights;

  • protection of our trademarks or trade names;

  • our reliance on access to intellectual property owned by third parties;

  • claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets or other proprietary information or claims asserting ownership of intellectual property that we regard as our own;

  • our ability to enforce our intellectual property rights in all jurisdictions;

  • other risks related to our indebtedness, corporate structure and ownership of our common stock; and

  • other factors described in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025.

Many of these factors are beyond our control. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, actual results, performance, or achievements may differ materially from those expressed or implied by forward-looking statements in this earnings release. The forward-looking statements included in this earnings release speak only as of the date of this release.

*NON-GAAP FINANCIAL MEASURES

This earnings release includes certain financial measures not presented in accordance with the generally accepted accounting principles in the United States (“GAAP”), including adjusted net income, adjusted net income margin, adjusted basic EPS, adjusted diluted EPS, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted segment income and adjusted segment income margin. These financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing the Company’s financial results. Hayward believes these non-GAAP measures provide analysts, investors and other interested parties with additional insight into the underlying trends of its business and assist these parties in analyzing the Company’s performance across reporting periods on a consistent basis by excluding items that it does not believe are indicative of its core operating performance, which allows for a better comparison against historical results and expectations for future performance. Management uses these non-GAAP measures to understand and compare operating results across reporting periods for various purposes including internal budgeting and forecasting, short and long-term operating planning, employee incentive compensation, and debt compliance. These measures should not be considered in isolation or as an alternative to net income, segment income or other measures of profitability, performance or financial condition under GAAP. You should be aware that the Company’s presentation of these measures may not be comparable to similarly titled measures used by other companies, which may be defined and calculated differently. See the appendix for a reconciliation of historical non-GAAP measures to the most directly comparable GAAP measures.

Reconciliation of full fiscal year 2026 adjusted diluted earnings per share outlook to diluted earnings per share is not being provided, as Hayward does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. The outlook for adjusted diluted earnings per share for full year 2026 is calculated in a manner consistent with the historical presentation of these measures, as shown in the appendix.

 

Hayward Holdings, Inc.

Unaudited Condensed Consolidated Balance Sheets

(Dollars in thousands. except per share data)

 

 

 

March 28, 2026

 

December 31, 2025

Assets

 

 

 

 

Current assets

 

 

 

 

Cash and cash equivalents

 

$

135,794

 

 

$

329,648

 

Short-term investments

 

 

94,935

 

 

 

69,462

 

Accounts receivable, net of allowances of $1,614 and $1,931, respectively

 

 

430,878

 

 

 

280,161

 

Inventories, net

 

 

229,032

 

 

 

210,739

 

Prepaid expenses

 

 

14,702

 

 

 

19,500

 

Income tax receivable

 

 

 

 

 

656

 

Other current assets

 

 

42,927

 

 

 

41,080

 

Total current assets

 

 

948,268

 

 

 

951,246

 

Property, plant, and equipment, net of accumulated depreciation of $130,634 and $125,807, respectively

 

 

165,466

 

 

 

164,560

 

Goodwill

 

 

949,778

 

 

 

951,197

 

Trademark

 

 

736,000

 

 

 

736,000

 

Customer relationships, net

 

 

172,865

 

 

 

178,126

 

Other intangibles, net

 

 

85,854

 

 

 

88,899

 

Other non-current assets

 

 

77,352

 

 

 

80,956

 

Total assets

 

$

3,135,583

 

 

$

3,150,984

 

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities

 

 

 

 

Current portion of long-term debt

 

$

11,053

 

 

$

13,261

 

Accounts payable

 

 

86,097

 

 

 

77,007

 

Accrued expenses and other liabilities

 

 

178,408

 

 

 

224,222

 

Income taxes payable

 

 

15,231

 

 

 

8,754

 

Total current liabilities

 

 

290,789

 

 

 

323,244

 

Long-term debt, net

 

 

942,756

 

 

 

943,547

 

Deferred tax liabilities, net

 

 

227,734

 

 

 

227,449

 

Other non-current liabilities

 

 

62,570

 

 

 

63,736

 

Total liabilities

 

 

1,523,849

 

 

 

1,557,976

 

Stockholders’ equity

 

 

 

 

Preferred stock, $0.001 par value, 100,000,000 authorized, no shares issued or outstanding as of March 28, 2026 and December 31, 2025

 

 

 

 

 

 

Common stock $0.001 par value, 750,000,000 authorized; 246,928,772 issued and 217,662,403 outstanding at March 28, 2026; 246,272,783 issued and 217,356,414 outstanding at December 31, 2025

 

 

247

 

 

 

247

 

Additional paid-in capital

 

 

1,113,530

 

 

 

1,109,522

 

Common stock in treasury; 29,266,369 and 28,916,369 at March 28, 2026 and December 31, 2025, respectively

 

 

(370,720

)

 

 

(363,182

)

Retained earnings

 

 

874,493

 

 

 

851,134

 

Accumulated other comprehensive loss

 

 

(5,816

)

 

 

(4,713

)

Total stockholders’ equity

 

 

1,611,734

 

 

 

1,593,008

 

Total liabilities and stockholders’ equity

 

$

3,135,583

 

 

$

3,150,984

 

 

Hayward Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations

(Dollars in thousands, except per share data)

 

 

 

Three Months Ended

 

 

March 28, 2026

 

March 29, 2025

Net sales

 

$

255,216

 

$

228,841

Cost of sales

 

 

136,515

 

 

123,588

Gross profit

 

 

118,701

 

 

105,253

Selling, general and administrative expense

 

 

62,586

 

 

56,995

Research, development and engineering expense

 

 

6,756

 

 

5,986

Acquisition and restructuring related expense

 

 

505

 

 

1,926

Amortization of intangible assets

 

 

6,366

 

 

6,835

Operating income

 

 

42,488

 

 

33,511

Interest expense, net

 

 

11,507

 

 

13,651

Loss on debt extinguishment

 

 

201

 

 

Other expense, net

 

 

666

 

 

1,179

Total other expense

 

 

12,374

 

 

14,830

Income from operations before income taxes

 

 

30,114

 

 

18,681

Provision for income taxes

 

 

6,755

 

 

4,348

Net income

 

$

23,359

 

$

14,333

 

 

 

 

 

Earnings per share

 

 

 

 

Basic

 

$

0.11

 

$

0.07

Diluted

 

$

0.11

 

$

0.06

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

Basic

 

 

217,359,824

 

 

215,962,018

Diluted

 

 

222,423,409

 

 

221,851,399

 

Hayward Holdings, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(Dollars in thousands)

 

 

 

Three Months Ended

 

March 28, 2026

 

March 29, 2025

Cash flows from operating activities

 

 

 

 

Net income

 

$

23,359

 

 

$

14,333

 

Adjustments to reconcile net income to net cash used in operating activities

 

 

 

 

Depreciation

 

 

5,949

 

 

 

6,263

 

Amortization of intangible assets

 

 

8,181

 

 

 

8,535

 

Amortization of deferred debt issuance fees

 

 

826

 

 

 

837

 

Stock-based compensation

 

 

3,624

 

 

 

2,935

 

Deferred income taxes (benefit)

 

 

(273

)

 

 

(709

)

Allowance for credit losses

 

 

(282

)

 

 

(5

)

Loss on sale/disposal of property, plant and equipment

 

 

689

 

 

 

11

 

Changes in operating assets and liabilities

 

 

 

 

Accounts receivable

 

 

(151,601

)

 

 

(13,931

)

Inventories

 

 

(18,915

)

 

 

(14,977

)

Other current and non-current assets

 

 

6,174

 

 

 

7,918

 

Accounts payable

 

 

9,220

 

 

 

13,519

 

Accrued expenses and other liabilities

 

 

(37,588

)

 

 

(30,579

)

Net cash used in operating activities

 

 

(150,637

)

 

 

(5,850

)

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

Purchases of property, plant, and equipment

 

 

(7,132

)

 

 

(5,517

)

Software development costs

 

 

(152

)

 

 

(595

)

Proceeds from sale of property, plant, and equipment

 

 

 

 

 

1

 

Purchases of short-term investments

 

 

(84,880

)

 

 

 

Proceeds from short-term investments

 

 

60,000

 

 

 

 

Net cash used in investing activities

 

 

(32,164

)

 

 

(6,111

)

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

Payments of long-term debt

 

 

(3,384

)

 

 

(590

)

Payments of short-term notes payable

 

 

 

 

 

(1,788

)

Purchase of common stock

 

 

(5,851

)

 

 

 

Taxes paid for net share settlement of equity awards

 

 

(1,687

)

 

 

(993

)

Other, net

 

 

(43

)

 

 

(364

)

Net cash used in financing activities

 

 

(10,965

)

 

 

(3,735

)

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(88

)

 

 

440

 

Change in cash and cash equivalents

 

 

(193,854

)

 

 

(15,256

)

Cash and cash equivalents, beginning of period

 

 

329,648

 

 

 

196,589

 

Cash and cash equivalents, end of period

 

$

135,794

 

 

$

181,333

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

Cash paid-interest

 

$

9,248

 

 

$

9,826

 

Cash paid-income taxes, net of refunds

 

 

(126

)

 

 

151

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

Accrued and unpaid purchases of property, plant, and equipment

 

 

1,891

 

 

 

2,232

 

Equipment financed under finance leases

 

 

 

 

 

103

 

Reconciliations

Consolidated Reconciliations

Net Income and Net Income Margin to Adjusted EBITDA and Adjusted EBITDA Margin Reconciliations (Non-GAAP)

Following is a reconciliation from net income and net income margin to adjusted EBITDA and adjusted EBITDA margin:

(Dollars in thousands)

 

Three Months Ended

 

 

March 28, 2026

 

March 29, 2025

Net income

 

$

23,359

 

 

$

14,333

 

Depreciation

 

 

5,949

 

 

 

6,263

 

Amortization

 

 

8,181

 

 

 

8,535

 

Interest expense, net

 

 

11,507

 

 

 

13,651

 

Income taxes

 

 

6,755

 

 

 

4,348

 

Loss on debt extinguishment

 

 

201

 

 

 

 

EBITDA

 

 

55,952

 

 

 

47,130

 

Stock-based compensation (a)

 

 

 

 

 

46

 

Currency exchange items (b)

 

 

(76

)

 

 

(6

)

Acquisition and restructuring related expense, net (c)

 

 

505

 

 

 

1,926

 

Other (d)

 

 

 

 

 

6

 

Total Adjustments

 

 

429

 

 

 

1,972

 

Adjusted EBITDA

 

$

56,381

 

 

$

49,102

 

 

 

 

 

 

Net income margin

 

 

9.2

%

 

 

6.3

%

Adjusted EBITDA margin

 

 

22.1

%

 

 

21.5

%

(a)

 

Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of Hayward’s initial public offering (the “IPO”).

(b)

 

Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts.

(c)

 

Adjustments in the three months ended March 28, 2026 were primarily driven by $0.5 million of costs related to termination benefits associated with the restructuring of several teams.

 

Adjustments in the three months ended March 29, 2025 were primarily driven by $1.7 million of transaction and integration costs associated with the acquisition of the business of ChlorKing HoldCo., LLC and related entities (“ChlorKing”) and $0.2 million of separation costs for the consolidation of operations in North America.

(d)

 

Adjustments in the three months ended March 29, 2025 were primarily driven by losses on the sale of assets.

Following is a reconciliation from net income and net income margin to adjusted EBITDA and adjusted EBITDA margin for the last 12 months:

(Dollars in thousands)

 

Last Twelve Months(e)

 

Fiscal Year

 

 

March 28, 2026

 

December 31, 2025

Net income

 

$

160,596

 

 

$

151,570

 

Depreciation

 

 

22,521

 

 

 

22,835

 

Amortization

 

 

34,097

 

 

 

34,451

 

Interest expense, net

 

 

48,138

 

 

 

50,282

 

Income taxes

 

 

35,474

 

 

 

33,067

 

Loss on debt extinguishment

 

 

201

 

 

 

 

EBITDA

 

 

301,027

 

 

 

292,205

 

Stock-based compensation (a)

 

 

11

 

 

 

57

 

Currency exchange items (b)

 

 

9

 

 

 

79

 

Acquisition and restructuring related expense, net (c)

 

 

2,465

 

 

 

3,886

 

Other (d)

 

 

3,046

 

 

 

3,052

 

Total Adjustments

 

 

5,531

 

 

 

7,074

 

Adjusted EBITDA

 

$

306,558

 

 

$

299,279

 

 

 

 

 

 

Net income margin

 

 

14.0

%

 

 

13.5

%

Adjusted EBITDA margin

 

 

26.7

%

 

 

26.7

%

(a)

 

Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of the IPO.

(b)

 

Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts.

(c)

 

Adjustments in the last 12 months ended March 28, 2026 were primarily driven by $1.6 million of compensation expenses for the retention of key employees acquired in the ChlorKing acquisition. Pursuant to the ChlorKing acquisition agreement, the full amount held in escrow was released to the specified key employees if such employees were employed by Hayward on the one-year anniversary of the acquisition. These payments were contingent on continued employment and were not dependent on the achievement of any metric or performance measure. The retention costs were recognized over the 12-month period from the date of acquisition. Other adjustments include $0.5 million of costs related to termination benefits associated with the restructuring of several teams, $0.4 million of costs related to restructuring actions in E&RW and $0.2 million of other acquisition and integration costs, partially offset by a reduction in expense of $0.2 million to finalize the relocation of the Company’s corporate office functions to Charlotte, North Carolina from Berkeley Heights, New Jersey.

 

Adjustments in the year ended December 31, 2025 were primarily driven by $3.1 million of compensation expenses for the retention of key employees acquired in the ChlorKing acquisition pursuant to the conditions in the acquisition agreement discussed above. Other adjustments for the year ended December 31, 2025 include $0.4 million of costs related to restructuring actions in E&RW, $0.3 million of separation costs for the consolidation of operations in North America and $0.2 million of other acquisition and integration costs, partially offset by a reduction in expense of $0.2 million to finalize the relocation of the Company’s corporate office functions to Charlotte, North Carolina from Berkeley Heights, New Jersey.

(d)

 

Adjustments in the last 12 months ended March 28, 2026 were primarily driven by $4.3 million for the settlement in principle of the securities class action litigation. Expenses beyond the $4.3 million related to this case are subject to insurance recoveries pursuant to the Company’s retention amount with its insurance carriers. Other adjustments include $1.3 million of income from insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility, partially offset by losses on the sale of assets.

 

Adjustments in the year ended December 31, 2025 were primarily driven by $4.3 million for the settlement in principle of the securities class action litigation. Expenses beyond the $4.3 million related to this case are subject to insurance recoveries pursuant to the Company’s retention amount with its insurance carriers. Other adjustments include $1.3 million of income from insurance proceeds related to flood damage associated with a hurricane at a contract manufacturing facility.

(e)

 

Items for the last 12 months ended March 28, 2026 were calculated by adding the items for the three months ended March 28, 2026 plus fiscal year ended December 31, 2025 and subtracting the items for the three months ended March 29, 2025.

Net Income, Net Income Margin and Diluted EPS toAdjusted Net Income, Adjusted Net Income Margin and Adjusted EPS Reconciliations (Non-GAAP)

Following is a reconciliation of net income and net income margin to adjusted net income and adjusted net income margin, and a reconciliation of earnings per share to adjusted earnings per share:

(Dollars in thousands, except per share data)

 

Three Months Ended

 

 

March 28, 2026

 

March 29, 2025

Net income

 

$

23,359

 

 

$

14,333

 

Tax adjustments (a)

 

 

(277

)

 

 

(182

)

Other adjustments and amortization:

 

 

 

 

Stock-based compensation (b)

 

 

 

 

 

46

 

Currency exchange items (c)

 

 

(76

)

 

 

(6

)

Acquisition and restructuring related expense, net (d)

 

 

505

 

 

 

1,926

 

Other (e)

 

 

 

 

 

6

 

Total other adjustments

 

 

429

 

 

 

1,972

 

Loss on debt extinguishment

 

 

201

 

 

 

 

Amortization

 

 

8,181

 

 

 

8,535

 

Tax effect (f)

 

 

(2,057

)

 

 

(2,548

)

Adjusted net income

 

$

29,836

 

 

$

22,110

 

 

 

 

 

 

Weighted average number of common shares outstanding, basic

 

 

217,359,824

 

 

 

215,962,018

 

Weighted average number of common shares outstanding, diluted

 

 

222,423,409

 

 

 

221,851,399

 

 

 

 

 

 

Basic EPS

 

$

0.11

 

 

$

0.07

 

Diluted EPS

 

$

0.11

 

 

$

0.06

 

 

 

 

 

 

Adjusted basic EPS

 

$

0.14

 

 

$

0.10

 

Adjusted diluted EPS

 

$

0.13

 

 

$

0.10

 

(a)

 

Tax adjustments for the three months ended March 28, 2026 reflected a normalized tax rate of 23.3% compared to the Company’s effective tax rate of 22.4%. The Company’s effective tax rate for the three months ended March 28, 2026 was primarily driven by tax benefits resulting from stock-based compensation. Tax adjustments for the three months ended March 29, 2025 reflected a normalized tax rate of 24.3% compared to the Company’s effective tax rate of 23.3%. The Company’s effective tax rate for the three months ended March 29, 2025 primarily included the tax benefits resulting from stock-based compensation.

(b)

 

Represents non-cash stock-based compensation expense related to equity awards issued to management, employees, and directors. The adjustment includes only expense related to awards issued under the 2017 Equity Incentive Plan, which were awards granted prior to the effective date of the IPO.

(c)

 

Represents unrealized non-cash (gains) losses on foreign denominated monetary assets and liabilities and foreign currency contracts.

(d)

 

Adjustments in the three months ended March 28, 2026 were primarily driven by $0.5 million of costs related to termination benefits associated with the restructuring of several teams.

 

Adjustments in the three months ended March 29, 2025 were primarily driven by $1.7 million of transaction and integration costs associated with the acquisition of the business of ChlorKing HoldCo., LLC and related entities (“ChlorKing”) and $0.2 million of separation costs for the consolidation of operations in North America.

(e)

 

Adjustments in the three months ended March 29, 2025 were primarily driven by losses on the sale of assets.

(f)

 

The tax effect represented the immediately preceding adjustments at the normalized tax rates as discussed in footnote (a) above.

Segment Reconciliations

Following is a reconciliation from segment income and segment income margin to adjusted segment income and adjusted segment income margin for the NAM and E&RW segments:

(Dollars in thousands)

 

Three Months Ended

 

Three Months Ended

 

 

March 28, 2026

 

March 29, 2025

 

 

NAM

 

E&RW

 

NAM

 

E&RW

Segment income

 

$

50,506

 

 

$

8,283

 

 

$

43,454

 

 

$

6,538

 

Depreciation

 

 

5,013

 

 

 

508

 

 

 

5,500

 

 

 

414

 

Amortization

 

 

1,816

 

 

 

 

 

 

1,700

 

 

 

 

Other (a)

 

 

 

 

 

 

 

 

3

 

 

 

 

Total adjustments

 

 

6,829

 

 

 

508

 

 

 

7,203

 

 

 

414

 

Adjusted segment income

 

$

57,335

 

 

$

8,791

 

 

$

50,657

 

 

$

6,952

 

 

 

 

 

 

 

 

 

 

Segment income margin %

 

 

24.1

%

 

 

18.2

%

 

 

23.2

%

 

 

15.7

%

Adjusted segment income margin %

 

 

27.3

%

 

 

19.4

%

 

 

27.1

%

 

 

16.6

%

(a)

 

Adjustments in the three months ended March 29, 2025 for NAM represented losses on the sale of assets, which the Company believes are not representative of its ongoing business operations.

 

Investor Relations:

Kevin Maczka

[email protected]

Media Relations:

Misty Zelent

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Technology Robotics Other Manufacturing Manufacturing

MEDIA:

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

Arkansas Children’s Hospital activated as the first clinical trial siteand now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD

DURHAM, N.C.–(BUSINESS WIRE)–
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene editing treatment for Duchenne muscular dystrophy (DMD), is being evaluated in the Phase 1/2 FUNCTION-DMD study.

PBGENE-DMD is Precision’s wholly owned in vivo gene editing program designed to potentially provide durable functional muscle improvement for patients with DMD who have mutations between exons 45 and 55, the largest molecular subset of boys living with the disease. The Phase 1/2 FUNCTION-DMD study will enroll ambulatory patients and is designed to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes.

“The activation of Arkansas Children’s Hospital marks a critical step in advancing PBGENE-DMD into the clinic and expanding access for patients and families who are looking for novel options to address this devastating genetic disease.” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “Dr. Aravindhan Veerapandiyan and the team at Arkansas Children’s Hospital bring deep experience in running clinical trials and research in Duchenne. As the inaugural site for the FUNCTION-DMD study, we are pleased to open screening and enrollment at this center while we continue to work to activate other trial sites for inclusion in the FUNCTION-DMD study.”

Arkansas Children’s is a Parent Project Muscular Dystrophy (PPMD)-certified Duchenne Care Center, recognized for delivering specialized, multidisciplinary care for patients with Duchenne muscular dystrophy. PPMD’s Certified Duchenne Care Center Program is intended to help ensure that participating centers maintain high standards in clinical and sub-specialty services, rapidly incorporate evidence-based knowledge, and provide standardized multidisciplinary Duchenne care. Additionally, Arkansas Children’s is a designated Muscular Dystrophy Association (MDA) Care Center, providing specialized, multidisciplinary care for neuromuscular diseases including diagnosis, personalized treatment plans, and comprehensive support for patients.

“Families living with Duchenne Muscular Dystrophy need access to both experienced multidisciplinary care and promising investigational studies that may address the underlying cause of disease,” said Aravindhan Veerapandiyan, M.D. “We are pleased to begin screening and enrollment for the FUNCTION-DMD study in patients from around the world who seek treatment at our site and look forward to working with Precision and eligible patients and families as we evaluate PBGENE-DMD.”

About FUNCTION-DMD Trial:

The Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients between the age of 2-7 with mutations between exons 45 and 55 representing up to 60% of boys with DMD. The objective of the FUNCTION-DMD study is to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes in patients afflicted with DMD. For more information about this clinical trial and contact information, please visit www.clinicaltrials.gov and search for NCT07429240.

About PBGENE-DMD, A Muscle-Targeted Excision Program

PBGENE-DMD is Precision’s development program for the treatment of DMD. DMD is a genetic disease caused by mutations in the dystrophin gene that prevent production of the dystrophin protein and affects approximately 15,000 patients in the U.S. alone. There are currently no approved therapies that can drive durable and significant functional improvements over time. PBGENE-DMD is designed to improve function by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene. The aim of this approach is to restore a near full-length functional dystrophin protein within the body that more closely resembles normal dystrophin as opposed to synthetic, truncated microdystrophin approaches with potentially minimal functional benefit. The Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients with mutations between exons 45 and 55 impacting up to 60% of boys with DMD. The clinical trial will employ an appropriate immune modulation regimen and safety monitoring program to treat ambulatory patients at world-class specialized DMD clinical sites.

PBGENE-DMD was granted Orphan Drug Designation by the FDA in July 2025. The PBGENE-DMD program is eligible for a Priority Review Voucher (PRV) via the Rare Pediatric Disease Priority Review Voucher (PRV) program, which was signed into law on February 3, 2026, as part of the Consolidated Appropriations Act of 2026. PBGENE-DMD received Fast Track designation from the FDA in February 2026.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations about expectations around timing of site activation, patient enrollment and data releases of PBGENE-DMD and the FUNCTION-DMD Trial; translation of results in preclinical studies of PBGENE-DMD to clinical studies in humans; the design of PBGENE-DMD to potentially provide durable functional muscle improvement for DMD patients with mutations in exons 45-55 impacting up to 60% of patients with DMD; the belief that activation at a center with a high level of specialized expertise is important to advance a novel therapy; the use of an appropriate immune modulation regimen; and the design of PBGENE-DMD, a first-in-class gene editing approach designed to address the underlying cause of Duchenne muscular dystrophy. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “belief”, “believe,” “contemplate,” “could,” “design,” “designed,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “strive,” “suggest,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators’ or other licensees’ ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators’ or other licensees’ development of product candidates; our or our collaborators’ or other licensees’ ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators’ and other licensees’ ability to enroll patients; changes in interim “top-line” and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees’ ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators’ or other licensees’ ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-K for the annual period ended December 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.govand the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Health Genetics Children Other Science Clinical Trials Research Biotechnology

MEDIA:

Logo
Logo

Ten-League International Holdings Limited Announces 1-for-10 Reverse Share Split Effective May 1, 2026

SINGAPORE, April 29, 2026 (GLOBE NEWSWIRE) — Ten-League International Holdings Limited (NASDAQ: TLIH) (“TLIH” or “we,” “our,” or the “Company”), a Singapore-based provider of turnkey project solutions, today announced that on April 6, 2026, its board of directors approved a reverse split of its ordinary shares, par value US$0.000025 (the “Ordinary Shares”), on a one-for-ten basis (the “Reverse Share Split”). The Company’s Ordinary Shares will begin trading on the Nasdaq Stock Market LLC (“Nasdaq”) on a post-split basis on May 1, 2026 under the symbol “TLIH” under a new CUSIP number – G8763W201.

As a result of the Reverse Share Split, each ten (10) issued and outstanding Ordinary Shares will be combined into one (1) Ordinary Share, automatically and without any action by shareholders. The Reverse Share Split will result in a proportional increase in par value from US$0.000025 per share to US$0.00025 per share and an adjustment of the Company’s authorized share capital to 2,000,000,000 Ordinary Shares with a par value of US$0.00025 each. After giving effect to the Reverse Share Split, the Company expects to have approximately 2,940,435 Ordinary Shares issued and outstanding. The Reverse Share Split is intended to increase the market price per share of the Company’s Ordinary Shares to allow the Company to maintain its Nasdaq listing.

No fractional shares will be issued as a result of the Reverse Share Split. Shareholders who would be entitled to a fractional share as a result of the Reverse Share Split shall have their entitlement rounded up to the nearest whole share.

The Reverse Share Split was approved by a vote of the Company’s shareholders at its extraordinary meeting of shareholders held on April 13, 2026.

The Company’s transfer agent, VStock Transfer, LLC, will act as the exchange agent. Adjustments made to Ordinary Shares represented by physical stock certificates can be made upon surrender of the certificate to the transfer agent. Please contact VStock Transfer, LLC for further information at (212) 828-8436.

About Ten-League International Holdings Limited

Ten-League International Holdings Limited is a Singapore-based provider of turnkey project solutions. The Company’s business primarily consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. The equipment is organized into four categories based on their functions and application scenarios: foundation equipment, hoist equipment, excavation equipment and port machinery. The Company also provides value-added engineering solutions under engineering consultancy services with the aim to address potential safety issues, enhance reliability and productivity and allow for customers to evaluate the performance of the equipment, the quality of the work completed and the progress of their projects. Ten-League’s mission is to provide high-quality equipment, value-added engineering solutions as well as maintenance and repair through continuous adaptation and application of new technologies. For more information, please visit the Company’s website: https://ir.ten-league.com.sg/.

Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

For more information, please contact:

Ten-League International Holdings Limited

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1 646-932-7242
Email: [email protected]